

CSL Limited
45 Poplar Road Parkville
Victoria 3052 Australia

T +613 9389 1911
F +613 9389 1434
www.csl.com.au



ASX Announcement

For immediate release

10 January 2019

Presentation to 2019 JP Morgan Healthcare Conference

Please find attached CSL Limited's presentation at the 2019 JP Morgan Healthcare Conference.

For further information, please contact:

Investors:

Mark Dehring
VP Investor Relations
CSL Limited
Telephone: +613 9389 3407
Email: mark.dehring@csl.com.au

Media:

Jemimah Brennan
Head of Communications, Asia Pacific
CSL Limited
Mobile +61 412 635 483
Email: jemimah.brennan@csl.com.au



CSL Limited

Paul Perreault, CEO and MD

JP Morgan Conference - January 9, 2019

LEGAL NOTICE

Forward looking statements

The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

Trademarks

Except where otherwise noted, brand names designated by a ™ or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.



CSL Today

5th Largest Global Biotech



Global #1 in plasma therapies

- \$30 billion industry



Global #2 in influenza vaccines

- \$6 billion industry



Strong Market Position

- Revenues ~\$8bn into more than 60 countries
- 8 major manufacturing sites in 6 countries
- Major capacity expansion underway
- Deep R&D pipeline fueling future growth



Solid Financial Position

- Net debt/EBITDA 1.3x
- A3 / A- credit rating (stable / stable)

Current Industry Themes

Plasma Supply Growth

Robust IG demand

Influenza Vaccine
Technology Shift

New Product Launches



March '16



May '16



June '17



Feb. '18

(US only)



March '18

Launch date denotes first country to launch globally

5 major launches in 24 months
Some of the **most successful** launches in the industry
Significant contribution to the business now...in future

R&D Productivity

Commercial Excellence

Therapeutic Platforms



Immunology and Neurology



Haematology and Thrombosis



Transplant



Respiratory



Cardiovascular and Metabolic






Plasma
Fractionation

Recombinant
Tech

Gene and Cell
Therapy

Immunoglobulin Therapy

Mechanism of action summary

	Pathogen Neutralisation	Reduction of Pathologic Ig	Complement Scavenging	FcγR Expression Modulation	Immune Cells Modulation	Cytokine Modulation
Ig Therapy						
IgG Fc Multimers						
FcRn Binding Agents						

 No Activity
  Possible Activity
  Activity

IDELVION[®] delivering in the real world



Annualised Bleed Rates in switched patients


FIX product	All FIX	rFIX-Fc	IDELVION
Prophylaxis-to-prophylaxis patients mean \pm SD	7.4 \pm 9.1 (n=34)	8.9 \pm 9.6 (n=12)	1.5 \pm 4.5 (n=34)
# with zero bleed (%)	6 (17.6)	2 (16.7)	23 (67.6)

Escobar et al, ISTH July 2018

- >85% of All-FIX therapies were administered every 7 days or more frequently
- 45% of IDELVION administration was every 14 days

- Further increased dosing flexibility anticipated
 - 21-day dosing submission planned 3Q 19

Transplant Strategy





Respiratory

Immunoglobulin Therapy


Expanding Benefit

Nebulised Ig – respiratory tract infections



- Concept: Prevention of viral and bacterial infections of the respiratory tract by inhaling polyclonal immunoglobulins
- Technical feasibility demonstrated

Potential indications for NebIg:

- Prevention of infections in PID patients
- Prevention of infection-related exacerbations in COPD and Bronchiectasis patients




CSL112 Program Timeline



- Actively recruiting and on track
- To date, patient activity at sites supports the Registry data

R&D Portfolio Balance



Seqirus - Differentiated Product Suite

Cell Culture (FLUCELVAX®)

- Significant reduction in disease
- Only scaled manufacturer
- Major capacity expansion underway

Adjuvant (FLUAD®)

- Seasonal vaccine – increased and broader immunogenicity, focussed on people 65yrs and older
- Pandemic vaccine – dose sparing
 - aH5N1c dose 1/12 of that required without adjuvant

the burden of flu disease 2017 - 2018

The estimated number of flu **illnesses** during the 2017-2018 season:

49 million

More than the combined populations of Texas, and Florida



The estimated number of flu **hospitalizations** during the 2017-2018 season:

960,000

More than the number of staffed hospital beds in the U.S.



The estimated number of flu **deaths** during the 2017-2018 season:

79,000

More than the average number of people who attend the Super Bowl each year




DATA: Influenza Division program impact report 2017-2018, <https://www.cdc.gov/flu/about/burden/index.html>



get vaccinated
www.cdc.gov/flu

Improvements in FLUCELVAX output

Number of doses of FLUCELVAX manufactured by calendar year



Growth Catalysts

PLASMA PROTEINS

- Ongoing robust demand
- Commercialization of 5 global product launches
- Grow China business
- R&D pipeline
 - CVD, Fc Multimer, transplant, gene therapy

INFLUENZA

- Product differentiation – FLUCELVAX®
- Sales shifting towards FLUAD® and QIV

EFFICIENCY & FLEXIBILITY

- Harness benefits from new technology investments
- Significant manufacturing capacity expansion
- Opening 30-35 collection centres in FY18

Outperformance Drivers



INNOVATION



EFFICIENCY



FLEXIBILITY